AbbVie Inc. Operating Cash Flow Margin

Operating Cash Flow Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow Margin growth rates and interactive chart.


Highlights and Quick Summary

  • Operating Cash Flow Margin for the quarter ending December 30, 2019 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow Margin decreased by -100.0%
  • Annual Operating Cash Flow Margin for 2019 was 0.0% (a -100.0% decrease from previous year)
  • Annual Operating Cash Flow Margin for 2018 was 40.99% (a 16.12% increase from previous year)
  • Annual Operating Cash Flow Margin for 2017 was 35.3% (a 28.55% increase from previous year)
  • Twelve month Operating Cash Flow Margin ending December 30, 2019 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Twelve month trailing Operating Cash Flow Margin decreased by -100.0% year-over-year
Trailing Operating Cash Flow Margin for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
0.0% 40.9% 41.1% 42.27%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow Margin of AbbVie Inc.

Most recent Operating Cash Flow Marginof ABBV including historical data for past 10 years.

Interactive Chart of Operating Cash Flow Margin of AbbVie Inc.

AbbVie Inc. Operating Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0% 53.72% 30.01% 38.54% 0.0%
2018 40.84% 54.93% 34.62% 33.34% 40.99%
2017 33.39% 46.76% 28.85% 32.15% 35.3%
2016 22.68% 22.61% 29.73% 35.72% 27.46%
2015 30.67% 36.26% 33.46% 31.45% 32.96%
2014 -10.6% 35.58% 34.86% 13.68% 17.78%
2013 24.36% 38.6% 43.41% 27.42% 33.35%
2012 18.08% 49.89% 34.74% 38.2% 34.52%
2011 21.56% 40.13% 50.24% 32.89% 35.81%
2010 0.0% 31.82%
2009 0.0% 37.76%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.